Fundz

MaxCyte to Acquire Akron BioProducts for $105 Million

PRIVATENov 10, 2026

Acquiring Company

MaxCyte

Acquired Company

Akron BioProducts

RockvilleAkronBiotechnologyHealth CareManufacturingBiotechnology

Description

MaxCyte, Inc. announced its plan to acquire Akron BioProducts LLC through a Securities Purchase Agreement. The transaction is valued at approximately $105 million in cash, along with additional stock and guaranteed deferred cash payments. The acquisition is subject to customary closing conditions and is expected to close before the end of 2026.

Who to call at MaxCyte, and when

When MaxCyte changes hands, the new owners review vendors, systems and leadership. That is when the door opens.

  • An alert the day MaxCyte raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at MaxCyte, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at MaxCyte. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

MaxCyte

Location

Rockville, Maryland, United States

About

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients’ lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today’s processes to innovate tomorrow’s solutions. Our ExPERTTM platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATxTM, STxTM, GTxTM and VLx TM; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical, and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on Twitter and LinkedIn.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment MaxCyte makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for MaxCyte's next move

Learn about Strategic plan

Frequently asked

Who acquired Akron BioProducts?

Akron BioProducts was acquired by MaxCyte, based in Rockville. The deal was reported on November 10, 2026. At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients’ lives. MaxCyte is privately held and operates in Biotechnology.

When did MaxCyte acquire Akron BioProducts?

MaxCyte's acquisition of Akron BioProducts was reported on November 10, 2026. MaxCyte, Inc. announced its plan to acquire Akron BioProducts LLC through a Securities Purchase Agreement. The transaction is valued at approximately $105 million in cash, along with additional stock and guaranteed deferred cash payments. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Akron BioProducts do?

Akron BioProducts LLC is a biotechnology firm specializing in cell and gene therapy products and services. It is privately held, operating in Manufacturing, and is based in Akron.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.